The outcome of 5-AZA against MDS and AML-MRC harboring blasts lower than 30% in a single institute

Shinichi Ogawa

Presentation information

Oral Session

Oral Session 3-11D MDS：AZA Treatment

Sun. Oct 13, 2019 3:40 PM - 4:40 PM No.11 (Tokyo International Forum, 5F G502)

Chair: Tomoko Hata (Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University)

[OS3-11D-6] The outcome of 5-AZA against MDS and AML-MRC harboring blasts lower than 30% in a single institute

Shinichi Ogawa¹, Kana Miyamoto¹, Yasuko Ogino¹, Takayoshi Itoh¹, Yasuhito Nanya², Seishi Ogawa², Manabu Kusakabe³, Shigeru Chiba³ (1.JA Toride General Medical Center, 2.Department of Pathology and Tumor Biology, Kyoto University, 3.Department of Hematology, University of Tsukuba)

Abstract password authentication.
Password is required to view the abstract. Please enter a password to authenticate.Password is written on a program book.